SAR425899 is a novel polypeptide with a co-excitatory effect on GCGR and GLP-1R, which can reduce blood glucose and HbA1c levels and reduce body weight in patients with T2D; however, it has an adverse effect on the gastrointestinal tract (110). Here, GLP1R is linked to type 2 diabetes mellitus.